|
A Phase 2b, Randomized, Double-blind, Parallel-group, Placebo controlled, Dose-finding, Multi-center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis in Patients who have had an Inadequate Response to Methotrexate |
peficitinib hydrobromide |
015K-CL-RA21 |
NCT01554696 EudraCT 2011-006018-15 |
Rheumatoid Arthritis |
Phase 2 |
|
|
|
|
|
February 2020 |